X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs CADILA HEALTHCARE - Comparison Results

BIOCON     Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON CADILA HEALTHCARE BIOCON /
CADILA HEALTHCARE
 
P/E (TTM) x 38.2 13.0 293.5% View Chart
P/BV x 6.0 2.9 206.4% View Chart
Dividend Yield % 0.2 1.4 13.7%  

Financials

 BIOCON    CADILA HEALTHCARE
EQUITY SHARE DATA
    BIOCON
Mar-18
CADILA HEALTHCARE
Mar-18
BIOCON /
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,188558 212.9%   
Low Rs305362 84.4%   
Sales per share (Unadj.) Rs68.7116.3 59.1%  
Earnings per share (Unadj.) Rs7.617.9 42.3%  
Cash flow per share (Unadj.) Rs14.023.1 60.4%  
Dividends per share (Unadj.) Rs1.003.50 28.6%  
Dividend yield (eoy) %0.10.8 17.6%  
Book value per share (Unadj.) Rs86.385.4 101.1%  
Shares outstanding (eoy) m600.001,023.74 58.6%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.94.0 274.8%   
Avg P/E ratio x98.925.7 384.2%  
P/CF ratio (eoy) x53.419.9 268.8%  
Price / Book Value ratio x8.65.4 160.6%  
Dividend payout %13.219.6 67.6%   
Avg Mkt Cap Rs m447,900470,664 95.2%   
No. of employees `0006.111.8 52.0%   
Total wages/salary Rs m9,31118,545 50.2%   
Avg. sales/employee Rs Th6,705.810,072.7 66.6%   
Avg. wages/employee Rs Th1,514.21,569.1 96.5%   
Avg. net profit/employee Rs Th736.91,547.7 47.6%   
INCOME DATA
Net Sales Rs m41,234119,049 34.6%  
Other income Rs m2,0621,132 182.2%   
Total revenues Rs m43,296120,181 36.0%   
Gross profit Rs m8,29128,475 29.1%  
Depreciation Rs m3,8515,388 71.5%   
Interest Rs m615911 67.5%   
Profit before tax Rs m5,88723,308 25.3%   
Minority Interest Rs m213628 33.9%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5695,644 27.8%   
Profit after tax Rs m4,53118,292 24.8%  
Gross profit margin %20.123.9 84.1%  
Effective tax rate %26.724.2 110.1%   
Net profit margin %11.015.4 71.5%  
BALANCE SHEET DATA
Current assets Rs m41,48682,005 50.6%   
Current liabilities Rs m21,41360,720 35.3%   
Net working cap to sales %48.717.9 272.3%  
Current ratio x1.91.4 143.5%  
Inventory Days Days6473 87.5%  
Debtors Days Days9498 95.8%  
Net fixed assets Rs m50,66183,703 60.5%   
Share capital Rs m3,0001,024 293.0%   
"Free" reserves Rs m48,80886,421 56.5%   
Net worth Rs m51,80887,445 59.2%   
Long term debt Rs m17,89825,551 70.0%   
Total assets Rs m99,897180,653 55.3%  
Interest coverage x10.626.6 39.8%   
Debt to equity ratio x0.30.3 118.2%  
Sales to assets ratio x0.40.7 62.6%   
Return on assets %5.210.6 48.5%  
Return on equity %8.720.9 41.8%  
Return on capital %9.622.0 43.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,05842,683 28.3%   
Fx outflow Rs m7,34811,242 65.4%   
Net fx Rs m4,71031,441 15.0%   
CASH FLOW
From Operations Rs m6,6219,193 72.0%  
From Investments Rs m-6,840-9,737 70.2%  
From Financial Activity Rs m-2,397515 -465.4%  
Net Cashflow Rs m-2,612-29 9,006.9%  

Share Holding

Indian Promoters % 40.4 74.8 54.0%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 8.3 101.2%  
FIIs % 10.7 5.9 181.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 11.0 180.9%  
Shareholders   109,995 44,069 249.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   DISHMAN PHARMA  WOCKHARDT  VENUS REMEDIES  DR. DATSONS LABS  GLENMARK PHARMA  

Compare BIOCON With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

US China Trade War Escalations and Election Results: Volatility Set to Rule(Podcast)

India could be the latest direct victim of the US-China trade war. The increasing escalations have already slowed down global growth.

Related Views on News

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (3QFY19); Net Profit Down 3.7% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 3.7% YoY). Sales on the other hand came in at Rs 36 bn (up 9.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 18.6% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (down 18.6% YoY). Sales on the other hand came in at Rs 30 bn (down 8.4% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

These Dividend Stocks Could Boost Your Returns Better Than You Can Imagine(Profit Hunter)

May 7, 2019

The art of dividend investing is a lot more than investing in companies with high dividend payouts or stocks with high dividend yields...

Limited Upside, Higher Downside(The Honest Truth)

May 6, 2019

The market's irrational reaction may present opportunities for a limited period of time.

3 Indian Stocks Replicating Amazon's Successful Strategy(The 5 Minute Wrapup)

May 10, 2019

The one critical element that has made Amazon a force to reckon with...

A Simple Checklist for Picking Great Dividend Stocks(Profit Hunter)

May 9, 2019

A filtered, neat list of high-dividend stocks with all this dirty work already done for you.

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


May 17, 2019 (Close)

TRACK BIOCON

BIOCON - STERLING BIOTECH COMPARISON

COMPARE BIOCON WITH

MARKET STATS